title: Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies).
abstract: The potential for the extraction of the plant lignan hydroxymatairesinol (HMR) in large scale from Norway spruce (Picea abies) has given us the opportunity to study the metabolism and biological actions of HMR in animals. HMR, the most abundant single component of spruce lignans, was metabolized to enterolactone (ENL) as the major metabolite in rats after oral administration. The amounts of urinary ENL increased with the dose of HMR (from 3 to 50 mg/kg), and only minor amounts of unmetabolized HMR isomers and other lignans were found in urine. HMR (15 mg/kg body wt po) given for 51 days decreased the number of growing tumors and increased the proportion of regressing and stabilized tumors in the rat dimethylbenz[a]anthracene-induced mammary tumor model. HMR (50 mg/kg body wt) did not exert estrogenic or antiestrogenic activity in the uterine growth test in immature rats. HMR also showed no antiandrogenic responses in the growth of accessory sex glands in adult male rats. Neither ENL nor enterodiol showed estrogenic or antiestrogenic activity via a classical alpha- or beta-type estrogen receptor-mediated pathway in vitro at < 1.0 microM. HMR was an effective antioxidant in vitro.
authors.affiliation: Department of Anatomy, University of Turku, Finland.
authors.forename: N M
authors.initials: NM
authors.lastname: Saarinen
authors.forename: A
authors.initials: A
authors.lastname: Wärri
authors.forename: S I
authors.initials: SI
authors.lastname: Mäkelä
authors.forename: C
authors.initials: C
authors.lastname: Eckerman
authors.forename: M
authors.initials: M
authors.lastname: Reunanen
authors.forename: M
authors.initials: M
authors.lastname: Ahotupa
authors.forename: S M
authors.initials: SM
authors.lastname: Salmi
authors.forename: A A
authors.initials: AA
authors.lastname: Franke
authors.forename: L
authors.initials: L
authors.lastname: Kangas
authors.forename: R
authors.initials: R
authors.lastname: Santti
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000652:urine; D000284:Administration, Oral; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D005663:Furans / Q000378:metabolism; D005837:Genitalia, Male / Q000187:drug effects / Q000254:growth & development; D017705:Lignans / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use / Q000652:urine; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D008517:Phytotherapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000378:metabolism; D014197:Trees / Q000737:chemistry*; D014599:Uterus / Q000187:drug effects / Q000254:growth & development
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005663:Furans; D017705:Lignans; D011960:Receptors, Estrogen; C419306:hydroxymatairesinol; C068935:matairesinol; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone